FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1812067939> ?p ?o ?g. }

• W1812067939 endingPage "2736" @default.
• W1812067939 startingPage "2731" @default.
• W1812067939 abstract "PURPOSE In this phase II study, the efficacy and tolerability of gemcitabine were studied in 44 patients with locally advanced or metastatic breast cancer. PATIENTS AND METHODS Of 40 patients assessable for response, 14 were chemotherapy-naive, seven had received adjuvant chemotherapy, and 19 had received one prior chemotherapy regimen for metastatic disease. Gemcitabine was administered as a 30-minute intravenous infusion once a week for 3 weeks followed by a 1-week rest every 4 weeks. The mean number of completed cycles administered was 2.7 and the mean dosage delivered was 725 mg/m2 per injection. Eighty-one percent of doses were delivered as scheduled. RESULTS There were three complete responses and seven partial responses, for an overall response rate of 25.0% (95% confidence interval [CI], 12.7% to 41.2%). Four patients were not assessable for efficacy (one had insufficient therapy, two had no bidimensionally measurable disease, and one had neither). All responses were independently validated by an external oncology review board. Responses were observed early in treatment, with a median time to response of 1.9 months. The median survival duration for all 40 assessable patients was 11.5 months. Hematologic toxicity was generally mild, with World Health Organization (WHO) grade 3 and 4 leukopenia occurring in 6.8% and 2.3% of patients and neutropenia in 23.3% and 7.0%, of patients, respectively. The only other grade 4 toxicities were infection and nausea and vomiting in one patient each. One patient was withdrawn due to shortness of breath, possibly drug-related. Flu-like symptoms, which were mild, transient, and treatable with acetominophen, were reported in 6.8% of patients. Only one patient developed alopecia of severity greater than WHO grade 2. CONCLUSION In view of the single-agent activity seen in advanced breast cancer, modest toxicity profile, and novel mechanism of action, gemcitabine deserves evaluation in breast cancer and is an ideal candidate for combination therapy." @default.
• W1812067939 created "2016-06-24" @default.
• W1812067939 creator A5033246132 @default.
• W1812067939 creator A5061033007 @default.
• W1812067939 creator A5079633934 @default.
• W1812067939 creator A5080571689 @default.
• W1812067939 creator A5081716847 @default.
• W1812067939 creator A5083546657 @default.
• W1812067939 creator A5085711583 @default.
• W1812067939 date "1995-11-01" @default.
• W1812067939 modified "2023-10-04" @default.
• W1812067939 title "Advanced breast cancer: a phase II trial with gemcitabine." @default.
• W1812067939 cites W1527742565 @default.
• W1812067939 cites W1558081606 @default.
• W1812067939 cites W1843618725 @default.
• W1812067939 cites W1857358013 @default.
• W1812067939 cites W1858072261 @default.
• W1812067939 cites W1872302450 @default.
• W1812067939 cites W1890647543 @default.
• W1812067939 cites W1976532235 @default.
• W1812067939 cites W2013403355 @default.
• W1812067939 cites W2018390295 @default.
• W1812067939 cites W2042859180 @default.
• W1812067939 cites W2066550282 @default.
• W1812067939 cites W2077627228 @default.
• W1812067939 cites W2084562398 @default.
• W1812067939 cites W2118512375 @default.
• W1812067939 cites W2128848742 @default.
• W1812067939 cites W2130164889 @default.
• W1812067939 cites W2154737435 @default.
• W1812067939 cites W2256088617 @default.
• W1812067939 cites W2270490184 @default.
• W1812067939 cites W2398292366 @default.
• W1812067939 cites W2483981519 @default.
• W1812067939 doi "https://doi.org/10.1200/jco.1995.13.11.2731" @default.
• W1812067939 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/7595731" @default.
• W1812067939 hasPublicationYear "1995" @default.
• W1812067939 type Work @default.
• W1812067939 sameAs 1812067939 @default.
• W1812067939 citedByCount "324" @default.
• W1812067939 countsByYear W18120679392012 @default.
• W1812067939 countsByYear W18120679392013 @default.
• W1812067939 countsByYear W18120679392014 @default.
• W1812067939 countsByYear W18120679392015 @default.
• W1812067939 countsByYear W18120679392016 @default.
• W1812067939 countsByYear W18120679392017 @default.
• W1812067939 countsByYear W18120679392018 @default.
• W1812067939 countsByYear W18120679392019 @default.
• W1812067939 countsByYear W18120679392020 @default.
• W1812067939 countsByYear W18120679392021 @default.
• W1812067939 countsByYear W18120679392022 @default.
• W1812067939 countsByYear W18120679392023 @default.
• W1812067939 crossrefType "journal-article" @default.
• W1812067939 hasAuthorship W1812067939A5033246132 @default.
• W1812067939 hasAuthorship W1812067939A5061033007 @default.
• W1812067939 hasAuthorship W1812067939A5079633934 @default.
• W1812067939 hasAuthorship W1812067939A5080571689 @default.
• W1812067939 hasAuthorship W1812067939A5081716847 @default.
• W1812067939 hasAuthorship W1812067939A5083546657 @default.
• W1812067939 hasAuthorship W1812067939A5085711583 @default.
• W1812067939 hasConcept C121608353 @default.
• W1812067939 hasConcept C126322002 @default.
• W1812067939 hasConcept C141071460 @default.
• W1812067939 hasConcept C197934379 @default.
• W1812067939 hasConcept C2775930923 @default.
• W1812067939 hasConcept C2776694085 @default.
• W1812067939 hasConcept C2777063308 @default.
• W1812067939 hasConcept C2778336483 @default.
• W1812067939 hasConcept C2778375690 @default.
• W1812067939 hasConcept C2780258809 @default.
• W1812067939 hasConcept C2780580376 @default.
• W1812067939 hasConcept C2780852908 @default.
• W1812067939 hasConcept C2780873365 @default.
• W1812067939 hasConcept C2781413609 @default.
• W1812067939 hasConcept C31760486 @default.
• W1812067939 hasConcept C530470458 @default.
• W1812067939 hasConcept C71924100 @default.
• W1812067939 hasConceptScore W1812067939C121608353 @default.
• W1812067939 hasConceptScore W1812067939C126322002 @default.
• W1812067939 hasConceptScore W1812067939C141071460 @default.
• W1812067939 hasConceptScore W1812067939C197934379 @default.
• W1812067939 hasConceptScore W1812067939C2775930923 @default.
• W1812067939 hasConceptScore W1812067939C2776694085 @default.
• W1812067939 hasConceptScore W1812067939C2777063308 @default.
• W1812067939 hasConceptScore W1812067939C2778336483 @default.
• W1812067939 hasConceptScore W1812067939C2778375690 @default.
• W1812067939 hasConceptScore W1812067939C2780258809 @default.
• W1812067939 hasConceptScore W1812067939C2780580376 @default.
• W1812067939 hasConceptScore W1812067939C2780852908 @default.
• W1812067939 hasConceptScore W1812067939C2780873365 @default.
• W1812067939 hasConceptScore W1812067939C2781413609 @default.
• W1812067939 hasConceptScore W1812067939C31760486 @default.
• W1812067939 hasConceptScore W1812067939C530470458 @default.
• W1812067939 hasConceptScore W1812067939C71924100 @default.
• W1812067939 hasIssue "11" @default.
• W1812067939 hasLocation W18120679391 @default.
• W1812067939 hasLocation W18120679392 @default.
• W1812067939 hasOpenAccess W1812067939 @default.

• next